About this trial
This study looks at using high doses of vitamin C along with a lower dose of melphalan, a chemotherapy drug, for patients with relapsed multiple myeloma. The goal is to see if this combination is safe and effective, especially since the melphalan dose is lower than usual. Researchers want to learn how well this treatment works and how it affects patients' quality of life.
The trial's ID number is NCT06313502. This is a Phase 1 trial, which means it is the first step in testing the safety and effectiveness of the treatment. The trial is regulated by the FDA, and it hopes to include about 18 participants.
Who can join
Adults aged 18 to 100 years can join this trial. It is open to both men and women who have had multiple treatments for multiple myeloma and still have active disease. Participants must have enough stem cells stored and must meet certain health criteria. The trial team will confirm if you are eligible to join.
Condition
Plasma Cell Disorder
Age group
Adult, Older adult
The study team makes the final call on eligibility.
What happens in the study
Everyone in this trial will receive high doses of vitamin C along with melphalan. Participants will first get a test dose of vitamin C, then one of three higher doses depending on their group. They will also receive melphalan before undergoing a stem cell transplant. After the transplant, additional doses of vitamin C will be given weekly for four weeks. The treatment is not given by chance; everyone will follow the same plan.
Where
This trial is running at 1 location in the United States. It is currently recruiting.
University of Arkansas for Medical Sciences
Little Rock, Arkansas